Bioxcel Therapeutics, INC Form 4 insider transactions

Javier Rodriguez, BioXcel Therapeutics' Chief Legal Officer, converted Restricted Stock Units into 68 shares of common stock over two days in December 2025.

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, converted Restricted Stock Units into common stock on December 14 and 15, 2025.

BioXcel Therapeutics Director David J. Mack acquired 1,694 shares of common stock on October 31, 2025, following the vesting of Restricted Stock Units.

BioXcel Therapeutics Director David J. Mack acquired 1,694 shares of common stock through the vesting of Restricted Stock Units.

BioXcel Therapeutics CEO and President Vimal Mehta reported the acquisition of common stock through the exercise of Restricted Stock Units on September 14 and 15, 2025.

BioXcel Therapeutics' CFO, Richard Steinhart, acquired additional common stock through the routine vesting of Restricted Stock Units.

BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, converted restricted stock units into common stock on September 14 and 15, 2025.

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, converted a total of 68 Restricted Stock Units into common stock on September 14 and 15, 2025.

BioXcel Therapeutics Director David J. Mack converted 1,693 Restricted Stock Units into common stock on August 31, 2025.

BioXcel Therapeutics' Chief Financial Officer, Richard I. Steinhart, received a grant of 9,000 Restricted Stock Units.

BioXcel Therapeutics, Inc. granted 9,000 Restricted Stock Units to Chief Legal Officer Javier Rodriguez, vesting in May 2026.

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, was granted 9,000 Restricted Stock Units (RSUs) on August 1, 2025, which will vest nine months from the grant date.

BioXcel Therapeutics CEO Vimal Mehta was granted 18,000 Restricted Stock Units, vesting in approximately nine months, as part of his compensation.

BioXcel Therapeutics Director David J. Mack converted 1,693 Restricted Stock Units into common stock on July 31, 2025, increasing his direct holdings of the company's shares.

BioXcel Therapeutics, Inc. CEO and President Vimal Mehta acquired 15,625 shares of common stock through the vesting of performance-based restricted stock units.

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, acquired 4,375 shares of common stock as previously granted performance stock units vested upon meeting performance objectives and continued service.

BioXcel Therapeutics' Chief Financial Officer, Richard Steinhart, increased his direct ownership of common stock by 5,000 shares through the vesting of performance and restricted stock units.

BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, acquired 5,000 shares of common stock through the vesting of performance and restricted stock units.

BioXcel Therapeutics Director David J. Mack converted 1,693 Restricted Stock Units into common stock on June 30, 2025, increasing his direct beneficial ownership of common shares.

BioXcel Therapeutics, Inc.'s Chief Financial Officer, Richard I. Steinhart, reported the acquisition of 68 shares of common stock through the routine vesting of Restricted Stock Units on June 14 and June 15, 2025, increasing his direct beneficial ownership.

BioXcel Therapeutics, Inc.'s Chief Scientific Officer, Frank Yocca, Ph.D., has increased his direct beneficial ownership of common stock through the vesting and conversion of Restricted Stock Units (RSUs).

BioXcel Therapeutics, Inc. CEO and President Vimal Mehta has reported the acquisition of common stock shares through the conversion of Restricted Stock Units (RSUs) as part of his compensation plan.

Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, Inc., reported the acquisition of 68 shares of common stock through the vesting of Restricted Stock Units on June 14 and June 15, 2025, increasing his direct beneficial ownership to 1,659 shares.

BioXcel Therapeutics Director David J. Mack converted 1,693 Restricted Stock Units into common stock, increasing his direct beneficial ownership of common shares to 11,851.

Director David J. Mack reports the acquisition and disposal of BioXcel Therapeutics stock and restricted stock units.

Vincent O'Neill, former Executive Vice President, Chief of Product Development and Medical Officer at BioXcel Therapeutics, reports changes in beneficial ownership following his departure, including the forfeiture of unvested stock options.

BioXcel Therapeutics CEO Vimal Mehta reports acquisition of stock options in a Form 4 filing with the SEC.

Richard Steinhart, CFO of BioXcel Therapeutics, reports the acquisition of restricted stock units and stock options.

Matthew Wiley, former Chief Commercial Officer of BioXcel Therapeutics, reports adjustments to his stock options following his termination of employment.

Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, acquired stock options and restricted stock units (RSUs) on July 22, 2024.